Comparison of IVIg and PLEX in patients with myasthenia gravis

Neurology

Volumn 76, Issue 23, 2011, Pages 2017-2023

  Barth, D ^a   Nabavi Nouri, M ^a   Ng, E ^a   Nwe, P ^a   Bril, V ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; HUMAN IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRIDOSTIGMINE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 79958765623     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31821e5505     Document Type: Article

References (23)

1. Vincent A, McConville J, Farrugia ME, et al. Antibodies in myasthenia gravis and related disorders. Ann NY Acad Sci 2003;998:324-335. (Pubitemid 37194175)
2. Vincent A, Leite MI. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 2005;18: 519-525. (Pubitemid 41476137)
3. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001;357:2122-2128. (Pubitemid 32607461)
4. Hohlfeld R, Wekerle H. The immunopathogenesis of myasthenia gravis. In: Engel AG, ed. Myasthenia Gravis and Myasthenic Disorders. New York: Oxford University Press; 1999:87-104.
5. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009;8:475-490.
6. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004;29:484-505. (Pubitemid 38451340)
7. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007;68:837-841. (Pubitemid 46568535)
8. Zinman L, Bril V. IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies. Ann NY Acad Sci 2008;1132:264-270. (Pubitemid 351841378)
9. Gajdos P, Simon N, de Rohan-Chabot P, Raphael JC, Goulon M. [Long-term effects of plasma exchange in myasthenia: results of a randomized study.] Presse Med 1983; 12:939-942. (Pubitemid 13120821)
10. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002; CD002275.
11. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2003;CD002277.
12. Jensen P, Bril V. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis. J Clin Neuromuscul Dis 2008;9:352-355. (Pubitemid 351416827)
13. Lisak RP. Plasma exchange in neurologic diseases. Arch Neurol 1984;41:654-657. (Pubitemid 14108775)
14. Howard JF Jr. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis. Neurology 1998;51: S30-S36. (Pubitemid 29001337)
15. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis: Myasthenia Gravis Clinical Study Group Ann Neurol 1997;41:789-796.
16. Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD. Myasthenic crisis: response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol 1993;50: 837-840. (Pubitemid 23229310)
17. Ronager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001;25:967-973. (Pubitemid 34107305)
18. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards: Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 2000;70:327-334.
19. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 1998;841: 769-772. (Pubitemid 28362935)
20. Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005;64:1968-1970. (Pubitemid 40800720)
21. Mullins LL, Carpentier MY, Paul RH, Sanders DB. Disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve 2008;38:947-956.
22. Wolfe GI, Barohn RJ, Foster BM, et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002;26:549-552.
23. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders. Neurology 2011;76:294-300.